Our press release here

Not to be published, distributed or disseminated, directly or indirectly, in the United States of America, Australia, Canada, South Africa and Japan

About Median Technologies

Pioneering innovative imaging services and Software as Medical Devices, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median’s offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis®, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit www.mediantechnologies.com.

Contacts

Median Technologies
Emmanuelle Leygues
VP, Corporate Marketing and Financial Communications
+33 6 10 93 58 88
emmanuelle.leygues@mediantechnologies.com

Press – Ulysse Communication
Bruno Arabian
+33 6 87 88 47 26
barabian@ulysse-communication.com
Nicolas Entz
+33 6 33 67 31 54
nentz@ulysse-communication.com

Investors – SEITOSEI-ACTIFIN
Ghislaine Gasparetto
+33 6 21 10 49 24
ghislaine.gasparetto@seitosei-actifin.com